AAOMS Annual Meeting

The FDA has approved Xermelo to be used in combination with somatostatin analogue therapy for the treatment of carcinoid syndrome diarrhea.

The FDA has approved once-daily Qtern for the treatment of patients with type 2 diabetes, as an adjunct to diet and exercise for the improvement of glycemic control.

The FDA has approved once-daily Qtern for the treatment of patients with type 2 diabetes, as an adjunct to diet and exercise for the improvement of glycemic control.

The FDA has approved once-daily Qtern for the treatment of patients with type 2 diabetes, as an adjunct to diet and exercise for the improvement of glycemic control.

The FDA has approved Spiriva Respimat for long-term, once-daily maintenance treatment of asthma in individuals aged 6 and older.

The FDA has approved Spiriva Respimat for long-term, once-daily maintenance treatment of asthma in individuals aged 6 and older.

The FDA has approved Spiriva Respimat for long-term, once-daily maintenance treatment of asthma in individuals aged 6 and older.

The FDA approved the injection Siliq (brodalumab) to treat adults with moderate to severe plaque psoriasis.

The FDA approved the injection Siliq (brodalumab) to treat adults with moderate to severe plaque psoriasis.

The FDA has approved Emflaza (deflazacort) tablets and oral suspension for the treatment of patients aged 5 years and older with Duchenne muscular dystrophy.